利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.037 秒)

    D-DIMER, TROPONIN, AND NT-PROBNP FOR PULMONARY EMBOLISM
    3.
    发明申请
    D-DIMER, TROPONIN, AND NT-PROBNP FOR PULMONARY EMBOLISM 失效
    D-DIMER，TROPONIN和NT-PROBNP用于肺动脉栓塞

    公开(公告)号：US20110129936A1

    公开(公告)日：2011-06-02

    申请号：US13020346

    申请日：2011-02-03

    申请人： Eberhard Spanuth ,  Boris Ivandic

    发明人： Eberhard Spanuth ,  Boris Ivandic

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6893 ,  G01N33/86 ,  G01N2333/4712 ,  G01N2333/58 ,  G01N2333/75 ,  G01N2800/226

    摘要： The present invention relates to a method of diagnosing acute pulmonary embolism (PE) in a subject including a) determining the amount of fibrin-fibrinogen degradation products, in particular D-dimer in a sample of the subject; b) determining the amount of a natriuretic peptide in a sample of the subject; c) determining the amount of a cardiac troponin in a sample of the subject; and d) comparing the amounts determined in steps a) to c) to reference amounts, thereby establishing the diagnosis. Included is also a method of deciding on a therapy of a subject diagnosed with PE and a method of monitoring the therapy.

    摘要翻译： 本发明涉及一种诊断受试者的急性肺栓塞（PE）的方法，包括：a）确定受试者样品中纤维蛋白原纤维蛋白原降解产物，特别是D-二聚体的量; b）确定受试者样品中利尿钠肽的量; c）确定受试者样品中心肌肌钙蛋白的量; 和d）将步骤a）至c）中确定的量与参考量进行比较，从而建立诊断。 包括也是确定被诊断为PE的受试者的治疗方法和监测治疗的方法。

    D-dimer, troponin, and NT-proBNP for pulmonary embolism
    4.
    发明授权
    D-dimer, troponin, and NT-proBNP for pulmonary embolism 失效
    D-二聚体，肌钙蛋白和NT-proBNP用于肺栓塞

    公开(公告)号：US08444932B2

    公开(公告)日：2013-05-21

    申请号：US13020346

    申请日：2011-02-03

    申请人： Eberhard Spanuth ,  Boris Ivandic

    发明人： Eberhard Spanuth ,  Boris Ivandic

    IPC分类号： G01N33/68 ,  G01N33/48

    CPC分类号： G01N33/6893 ,  G01N33/86 ,  G01N2333/4712 ,  G01N2333/58 ,  G01N2333/75 ,  G01N2800/226

    摘要： The present invention relates to a method of diagnosing acute pulmonary embolism (PE) in a subject including a) determining the amount of fibrin-fibrinogen degradation products, in particular D-dimer in a sample of the subject; b) determining the amount of a natriuretic peptide in a sample of the subject; c) determining the amount of a cardiac troponin in a sample of the subject; and d) comparing the amounts determined in steps a) to c) to reference amounts, thereby establishing the diagnosis. Included is also a method of deciding on a therapy of a subject diagnosed with PE and a method of monitoring the therapy.

    摘要翻译： 本发明涉及一种诊断受试者的急性肺栓塞（PE）的方法，包括：a）确定受试者样品中纤维蛋白原纤维蛋白原降解产物，特别是D-二聚体的量; b）确定受试者样品中利尿钠肽的量; c）确定受试者样品中心肌肌钙蛋白的量; 和d）将步骤a）至c）中确定的量与参考量进行比较，从而建立诊断。 包括也是确定被诊断为PE的受试者的治疗方法和监测治疗的方法。

    D-DIMER, TROPONIN, AND NT-PROBNP FOR PULMONARY EMBOLISM
    5.
    发明申请
    D-DIMER, TROPONIN, AND NT-PROBNP FOR PULMONARY EMBOLISM 审中-公开
    D-DIMER，TROPONIN和NT-PROBNP用于肺动脉栓塞

    公开(公告)号：US20130236916A1

    公开(公告)日：2013-09-12

    申请号：US13869464

    申请日：2013-04-24

    申请人： Eberhard Spanuth ,  Boris Ivandic

    发明人： Eberhard Spanuth ,  Boris Ivandic

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6893 ,  G01N33/86 ,  G01N2333/4712 ,  G01N2333/58 ,  G01N2333/75 ,  G01N2800/226

    摘要： The present invention relates to a method of diagnosing acute pulmonary embolism (PE) in a subject including a) determining the amount of fibrin-fibrinogen degradation products, in particular D-dimer in a sample of the subject; b) determining the amount of a natriuretic peptide in a sample of the subject; c) determining the amount of a cardiac troponin in a sample of the subject; and d) comparing the amounts determined in steps a) to c) to reference amounts, thereby establishing the diagnosis. Included is also a method of deciding on a therapy of a subject diagnosed with PE and a method of monitoring the therapy.

    摘要翻译： 本发明涉及一种诊断受试者的急性肺栓塞（PE）的方法，包括：a）确定受试者样品中纤维蛋白原纤维蛋白原降解产物，特别是D-二聚体的量; b）确定受试者样品中利尿钠肽的量; c）确定受试者样品中心肌肌钙蛋白的量; 和d）将步骤a）至c）中确定的量与参考量进行比较，从而建立诊断。 包括也是确定被诊断为PE的受试者的治疗方法和监测治疗的方法。

    CARDIAC HORMONES FOR ASSESSING CARDIOVASCULAR RISK
    7.
    发明申请
    CARDIAC HORMONES FOR ASSESSING CARDIOVASCULAR RISK 有权
    用于评估心血管风险的心脏病患者

    公开(公告)号：US20090023591A1

    公开(公告)日：2009-01-22

    申请号：US12202733

    申请日：2008-09-02

    申请人： Eberhard Spanuth

    发明人： Eberhard Spanuth

    IPC分类号： C40B30/00 ,  G01N33/68 ,  C12Q1/02

    CPC分类号： G01N33/6887 ,  G01N33/6893 ,  G01N2800/32 ,  Y10S436/817

    摘要： The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a cox-2-inhibiting compound, in particular an NSAID, selective cox-2 inhibitor, or steroid. More particularly, the present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a selective cox-2 inhibitor, comprising the steps of (a) measuring, preferably in vitro, the level of a cardiac hormone, (b) diagnosing the risk of the patient by comparing the measured level to known levels associated with different grades of risk in a patient. The most preferred cardiac hormone in the context of the present invention is NT-proBNP. Furthermore, the present invention relates to a method for diagnosing the risk of a patient to suffer from a cardiovascular complication as a consequence of administration of a cox-2 inhibiting compound, comprising the steps of (a) measuring the level of a cardiac hormone, (b) diagnosing the risk of the patient by comparing the measured level to known levels associated with different grades of risk in a patient.

    摘要翻译： 本发明涉及心脏激素，特别是利尿钠肽用于诊断作为用于施用cox-2抑制化合物，特别是NSAID，选择性cox-2抑制剂的候选者的患者的心血管风险的用途，或 类固醇。 更具体地说，本发明涉及使用心脏激素，特别是利尿钠肽来诊断作为选择性cox-2抑制剂的候选者的患者的心血管风险，其包括以下步骤：（a）优选 在体外，心脏激素的水平，（b）通过将患者的不同等级风险相关的测量水平与已知水平进行比较来诊断患者的风险。 本发明上下文中最优选的心脏激素是NT-proBNP。 此外，本发明涉及一种用于诊断作为施用cox-2抑制化合物的结果的患有心血管并发症的患者的风险的方法，包括以下步骤：（a）测量心脏激素的水平， （b）通过将患者的不同等级风险相关的测量水平与已知水平进行比较来诊断患者的风险。

    Cardiac hormones for assessing cardiovascular risk
    8.
    发明申请
    Cardiac hormones for assessing cardiovascular risk 有权
    用于评估心血管风险的心脏激素

    公开(公告)号：US20060234300A1

    公开(公告)日：2006-10-19

    申请号：US11297923

    申请日：2005-12-08

    申请人： Eberhard Spanuth

    发明人： Eberhard Spanuth

    IPC分类号： G01N33/53

    CPC分类号： G01N33/6887 ,  G01N33/6893 ,  G01N2800/32 ,  Y10S436/817

    摘要： The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for adminitstration of a cox-2-inhibiting compound, in particular an NSAID, selective cox-2 inhibitior, or steroid. More particularly, the present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a selective cox-2 inhibitor, comprising the steps of (a) measuring, preferably in vitro, the level of a cardiac hormone, (b) diagnosing the risk of the patient by comparing the measured level to known levels associated with different grades of risk in a patient. The most preferred cardiac hormone in the context of the present invention is NT-proBNP. Furthermore, the present invention relates to a method for diagnosing the risk of a patient to suffer from a cardiovascular complication as a consequence of administration of a cox-2 inhibiting compound, comprising the steps of (a) measuring the level of a cardiac hormone, (b) diagnosing the risk of the patient by comparing the measured level to known levels associated with different grades of risk in a patient.

    摘要翻译： 本发明涉及心脏激素，特别是利尿钠肽用于诊断作为治疗cox-2抑制化合物，特别是NSAID，选择性cox-2抑制剂的候选者的患者的心血管风险的用途，或 类固醇。 更具体地说，本发明涉及使用心脏激素，特别是利尿钠肽来诊断作为选择性cox-2抑制剂的候选者的患者的心血管风险，其包括以下步骤：（a）优选 在体外，心脏激素的水平，（b）通过将患者的不同等级风险相关的测量水平与已知水平进行比较来诊断患者的风险。 本发明上下文中最优选的心脏激素是NT-proBNP。 此外，本发明涉及一种用于诊断作为施用cox-2抑制化合物的结果的患有心血管并发症的患者的风险的方法，包括以下步骤：（a）测量心脏激素的水平， （b）通过将患者的不同等级风险相关的测量水平与已知水平进行比较来诊断患者的风险。

    Cardiac hormones for assessing cardiovascular risk
    9.
    发明授权
    Cardiac hormones for assessing cardiovascular risk 有权
    用于评估心血管风险的心脏激素

    公开(公告)号：US08062896B2

    公开(公告)日：2011-11-22

    申请号：US12202733

    申请日：2008-09-02

    申请人： Eberhard Spanuth

    发明人： Eberhard Spanuth

    IPC分类号： G01N33/00 ,  G01N33/53

    CPC分类号： G01N33/6887 ,  G01N33/6893 ,  G01N2800/32 ,  Y10S436/817

    摘要： The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a cox-2-inhibiting compound, in particular an NSAID, selective cox-2 inhibitor, or steroid. More particularly, the present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a selective cox-2 inhibitor and further provides methods for diagnosing the risk of a patient to suffer from a cardiovascular complication as a consequence of administration of a cox-2 inhibiting compound.

    摘要翻译： 本发明涉及心脏激素，特别是利尿钠肽用于诊断作为用于施用cox-2抑制化合物，特别是NSAID，选择性cox-2抑制剂的候选者的患者的心血管风险的用途，或 类固醇。 更具体地，本发明涉及心脏激素，特别是钠尿肽用于诊断作为选择性cox-2抑制剂的候选者的患者的心血管风险的用途，并进一步提供用于诊断患者风险的方法 作为施用cox-2抑制化合物的结果而患有心血管并发症。

    Use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs
    10.
    发明申请
    Use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs 审中-公开
    使用心脏激素来评估与抗炎药物相关的心血管风险

    公开(公告)号：US20060166303A1

    公开(公告)日：2006-07-27

    申请号：US11041671

    申请日：2005-01-24

    申请人： Eberhard Spanuth

    发明人： Eberhard Spanuth

    IPC分类号： C12Q1/26

    CPC分类号： G01N33/6893 ,  G01N2333/58 ,  G01N2800/32

    摘要： The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a selective Cox-2 inhibitor, comprising the steps of a) measuring, preferably in vitro, the level of a cardiac hormone, b) diagnosing the risk of the patient by comparing the measured level to known levels associated with different grades of risk in a patient. The most preferred cardiac hormone in the context of the present invention is NT-proBNP.

    摘要翻译： 本发明涉及心脏激素，特别是利尿钠肽用于诊断作为选择性Cox-2抑制剂的候选者的患者的心血管风险的用途，其包括以下步骤：a）优选地在体外测量 心脏激素的水平，b）通过将测量的水平与与患者的不同等级的风险相关联的已知水平进行比较来诊断患者的风险。 本发明上下文中最优选的心脏激素是NT-proBNP。